Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

BACKGROUND: The global Phase III LUX-Lung 8 trial (ClinicalTrials.gov: NCT01523587) identified significant improvements in progression-free survival (PFS), overall survival (OS), and patient-reported outcomes (PROs) with second-line afatinib vs erlotinib in patients with advanced squamous cell carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Li, Wei, Zhou, Caicun, Hu, Cheng-Ping, Qin, Shukui, Cheng, Gang, Feng, Jifeng, Wang, Jie, Cseh, Agnieszka, Peil, Barbara, Gibson, Neil, Ehrnrooth, Eva, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292388/
https://www.ncbi.nlm.nih.gov/pubmed/30573970
http://dx.doi.org/10.2147/OTT.S161506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292388/
https://www.ncbi.nlm.nih.gov/pubmed/30573970
http://dx.doi.org/10.2147/OTT.S161506

Ejemplares similares